5 AMINO-MQ1

So What Does This Actually Mean?

Plain English summary — no PhD required

5-Amino-1MQ is a small molecule (not a peptide) that blocks an enzyme called NNMT — essentially releasing a metabolic brake that keeps fat cells in storage mode. In animal studies, it reversed obesity without any change in food intake, making it one of the most mechanistically interesting metabolic research compounds in the current literature.

What It Does

NNMT is an enzyme that is overactive in obese fat tissue. When it runs too fast, it drains the body's methyl pool and diverts a key NAD+ building block away from energy metabolism. 5-Amino-1MQ blocks NNMT, which preserves NAD+ levels and activates SIRT1 — a longevity-associated enzyme that tells fat cells to burn fat instead of store it.

Why It Matters

Most fat loss interventions work by suppressing appetite (GLP-1 agonists, stimulants) or increasing energy expenditure through stimulation. 5-Amino-1MQ works differently: it reprograms the metabolic behavior of fat cells themselves at the NAD+ and epigenetic level. In the key 2018 mouse study, obese mice lost significant fat mass in 11 days without eating less — a result with no parallel in appetite-based interventions.

The Bottom Line

5-Amino-1MQ has a well-characterized molecular mechanism, strong animal study data, and a compelling differentiated profile versus GLP-1 agonists. No human clinical trials have been completed as of 2026. It remains a research compound with significant scientific interest.

Overview

What is 5-Amino-1MQ?

5-Amino-1MQ (5-amino-1-methylquinolinium) is a selective small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that plays a central role in cellular methylation balance, NAD+ precursor availability, and adipose tissue metabolism. Unlike most compounds in the peptide research space, 5-Amino-1MQ is not a peptide — it is a quinolinium-based small molecule with a molecular weight of 174.20 Da.

NNMT is overexpressed in white adipose tissue in obese individuals, where it consumes S-adenosylmethionine (SAM) — the body's primary methyl donor — to methylate nicotinamide, effectively draining the methyl pool and reducing NAD+ precursor availability. By selectively inhibiting NNMT, 5-Amino-1MQ preserves SAM and NAD+ precursors, creating a metabolic environment that favors fat oxidation over fat storage. In the pivotal 2018 animal study by Neelakantan et al., systemic treatment with 5-Amino-1MQ reversed diet-induced obesity in mice within 11 days without any reduction in food intake.

Key Takeaways

• 5-Amino-1MQ (5-amino-1-methylquinolinium, MW 174.20 Da) is a selective small-molecule inhibitor of NNMT (nicotinamide N-methyltransferase) — it is a small molecule, not a peptide.

• Primary mechanism: inhibits NNMT to preserve SAM (the cellular methyl donor) and redirect nicotinamide into NAD+ synthesis, elevating cellular NAD+ and activating SIRT1-mediated fat oxidation.

• Pivotal 2018 study (Neelakantan et al.): reversed diet-induced obesity in mice at 20 mg/kg over 11 days without reducing food intake — fat loss was purely metabolic, not appetite-mediated.

• Distinct from GLP-1 agonists: does not suppress appetite or act on the gut-brain axis. Works specifically on adipose tissue metabolism through NAD+ and epigenetic mechanisms.

• No completed human clinical trials as of 2026; all efficacy data is from animal models. Research-only compound.

Composition

Molecular Composition

Amino Acid Sequence

Small molecule (not a peptide) — MW 174.20 Da

5-Amino-1MQ (5-amino-1-methylquinolinium) is a synthetic small molecule with the molecular formula C10H10N2 and molecular weight of 174.20 Da. It is structurally derived from the quinolinium scaffold — a bicyclic aromatic system — with an amino group at the 5-position and a methyl group at the 1-position nitrogen. This specific substitution pattern confers high selectivity for NNMT over related methyltransferase enzymes.

The compound is membrane-permeable, allowing it to enter cells and access intracellular NNMT without requiring specialized delivery systems. It is supplied as a lyophilized powder at ≥99% purity, verified by independent third-party certificate of analysis.

Mechanism of Action

How Does It Work?

!

5-Amino-1MQ blocks NNMT to preserve NAD+ precursors and redirect adipose tissue metabolism away from fat storage toward fat oxidation — without affecting appetite.

5-Amino-1MQ inhibits NNMT (nicotinamide N-methyltransferase), an enzyme that catalyzes the N-methylation of nicotinamide using S-adenosylmethionine (SAM) as the methyl donor, producing 1-methylnicotinamide (MNA) and S-adenosylhomocysteine (SAH) as products.

In metabolically dysregulated adipose tissue, NNMT is overexpressed and consumes large quantities of SAM. This creates two downstream problems: (1) SAM depletion reduces the availability of methyl groups for other critical methylation reactions, including DNA and histone methylation; and (2) nicotinamide — a NAD+ precursor — is diverted away from the NAD+ synthesis pathway into the methylation pathway, reducing cellular NAD+ levels.

By inhibiting NNMT, 5-Amino-1MQ: (1) Preserves SAM, restoring methylation capacity for epigenetic regulation; (2) Redirects nicotinamide back into the NAD+ synthesis pathway, elevating cellular NAD+ levels; (3) Activates SIRT1 (a NAD+-dependent deacetylase), which promotes fatty acid oxidation and inhibits adipogenesis; (4) Reduces adipocyte size and white adipose tissue mass without affecting food intake.

This mechanism is distinct from GLP-1 receptor agonists (which suppress appetite) and from stimulants (which increase energy expenditure through sympathomimetic effects). 5-Amino-1MQ works specifically on the metabolic programming of adipose tissue at the epigenetic and NAD+ metabolism level.

5-Amino-1MQ Mechanism of Action — Simplified signaling pathway diagram. For research reference only.

"Treatment of diet-induced obese mice systemically with a potent NNMT inhibitor (5-amino-1-methylquinolinium) significantly reduced body weight and white adipose mass, decreased adipocyte size, and lowered plasma cholesterol and triglycerides — without changes in food intake." — Neelakantan et al., Biochemical Pharmacology, 2018